Olokizumab: Difference between revisions
CSV import |
No edit summary |
||
| Line 25: | Line 25: | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | {{No image}} | ||
Latest revision as of 13:04, 18 March 2025
Olokizumab is a humanized monoclonal antibody designed for the treatment of Rheumatoid arthritis. It is developed by R-Pharm and UCB.
Mechanism of Action[edit]
Olokizumab works by targeting and inhibiting the IL-6 cytokine, a protein that plays an important role in the inflammatory response of the immune system. By blocking the action of IL-6, Olokizumab can reduce inflammation and slow the progression of rheumatoid arthritis.
Clinical Trials[edit]
Olokizumab has undergone Phase III clinical trials for the treatment of rheumatoid arthritis. The trials have shown that Olokizumab is effective in reducing the symptoms of rheumatoid arthritis and improving the quality of life for patients.
Side Effects[edit]
Like all medications, Olokizumab can cause side effects. The most common side effects reported in clinical trials include upper respiratory tract infections, nasopharyngitis, and injection site reactions.
Approval[edit]
Olokizumab has been approved for use in Russia and is currently under review by the EMA and the FDA in the United States.
